Pulmonary Hypertension In Chronic Obstructive Pulmonary Disease: Pulmonary Hyperinflation, Gas Trapping And Disproportionate Pulmonary Hypertension.
Funder
National Health and Medical Research Council
Funding Amount
$103,583.00
Summary
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in Australia. Raised blood pressure in the lungs (pulmonary hypertension, PH) predicts a worse prognosis in patients with COPD. The mechanisms contributing to PH are incompletely understood. We aim to determine the role of lung hyperinflation in contributing to the development of PH in COPD. We also aim to identify a sub-group of patients that develop severe PH which may benefit from specific therapy.
Pulmonary Artery Pulsatility As A Predictor Of Survival Following Hospitalized Exacerbation Of Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Many patients with Chronic Obstructive Pulmonary Disease (COPD) also have elevated lung blood pressures, or pulmonary hypertension (PH). Having both conditions increases the risk of death. It is difficult to diagnose PH in COPD. We will be using a new Computed Tomography (X-ray imaging) technique to investigate a marker of PH called ‘pulmonary artery pulsatility’. If PH can be diagnosed easily and accurately new treatments can be devised and researched potentially improving outcomes in COPD.
Targeting IL-33 In Chronic Obstructive Pulmonary Disease (COPD), Chronic Asthma And Idiopathic Pulmonary Fibrosis (IPF)
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Lung diseases (emphysema, severe asthma & pulmonary fibrosis) are major burdens on Australian community and economy. Airway wounding is a key feature of all these diseases. Patients experience severe breathlessness seriously impacting quality of life and frequently leading to death. We will assess the potential of a new target (IL-33), & therapy (anti-IL-33) in suppressing wounding in experimental models and human tissues. This may lead to a new treatment to reverse and/or prevent lung diseases.
This program of work focuses on smoking related lung diseases including chronic bronchitis and emphysema, and lung cancer, as well as diseases affecting the blood vessels in the lungs. The work includes basic cell biology and human clinical trials.There is a high likelihood that new approaches to treating lung disease will emerge.
Development Of Guanylate Cyclase Activators For The Treatment Of Pulmonary Arterial Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$137,684.00
Summary
Pulmonary arterial hypertension (PAH) is a life threatening condition with few treatment options. It is marked by shortness of breath and reduced energy as a result of an unexplained constriction of the blood vessels in the lung. This results in reduced life expectancy. We are developing a new treatment that will relax the blood vessels in the lung to improve quality and length of life.
Providing Translatable Evidence To Advance Prevention And Management Of COPD: A Longitudinal Study From The 1st To 7th Decade Of Life
Funder
National Health and Medical Research Council
Funding Amount
$2,893,320.00
Summary
Chronic obstructive pulmonary disease (COPD) makes breathing difficult and reduces wellbeing. People are more likely to get COPD from the age of 60 years, but we do not know why and who. Our study will develop tools to identify early who will develop COPD by 60 years. We will also develop a tool to identify 60-year-old individuals whose lung function is declining faster than normal. These findings will help us to better prevent and manage COPD.
Preventing Complications Of Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$310,914.00
Summary
Chronic obstructive pulmonary disease (COPD) is a devastating lung disease that affects smokers. Lung complications and complications in other organs occur commonly. This study will examine factors that lead to exacerbations of COPD, and test the effectiveness of early diagnosis of coronary artery disease using CT scans.
Breathing In Chronic Heart Failure: Is There Novel Pulmonary Compensation?
Funder
National Health and Medical Research Council
Funding Amount
$312,021.00
Summary
Chronic heart failure (CHF) is a growing modern epidemic and therefore a costly health burden in Australia. Not only is it associated with a high mortality rate, symptoms of CHF are a major cause of patient suffering. Shortness of breath and exercise intolerance are both indicators of a link between CHF and lung function. There are a number of different ways in which CHF may be impacting on breathing and in this project we will be utilising an animal model to examine some of them. Firstly, the l ....Chronic heart failure (CHF) is a growing modern epidemic and therefore a costly health burden in Australia. Not only is it associated with a high mortality rate, symptoms of CHF are a major cause of patient suffering. Shortness of breath and exercise intolerance are both indicators of a link between CHF and lung function. There are a number of different ways in which CHF may be impacting on breathing and in this project we will be utilising an animal model to examine some of them. Firstly, the lung secretes a substance called surfactant which assists in normal breathing by decreasing surface tension in the lung. Previous studies in our laboratory have suggested an increase in surfactant production during CHF. In this project we will further examine this process to see if increased surfactant can aid breathing by decreasing surface tension during CHF. Secondly, we will examine the contribution made by the chest wall, increased heart size, lung volume and blood pressure during CHF on breathing. Thirdly, one of the problems thought to inhibit breathing in CHF patients is an increase in fluid in the lungs. The final stage of this project will examine the trasport of fluid into and out of the lung during CHF. This project will not only increase our understanding of the processes affecting breathing in response to CHF, but will also provide information for the development of potential therapeutic targets.Read moreRead less